The objective of this study is to determine the effect of consumption of drinks with varying amounts of glycerol and electrolytes on fluid balance at rest.

Start Date25 Jan 2024

Sponsor / Collaborator

PepsiCo Global R&D

100 Clinical Results associated with Glycerin

100 Translational Medicine associated with Glycerin

100 Patents (Medical) associated with Glycerin

3,273

Literatures (Medical) associated with Glycerin

01 Mar 2024·Cryobiology

Cryopreserved red blood cells maintain allosteric control of oxygen binding when utilizing trehalose as a cryoprotectant

Article

Author: Kopechek, Jonathan A ; Elder, Charles A ; Almosawi, Mustafa ; Wolkers, Willem F ; Janis, Brett R ; Smith, Jensen S ; Mills, Ethan ; Menze, Michael A

One of the most common life-saving medical procedures is a red blood cell (RBC) transfusion. Unfortunately, RBCs for transfusion have a limited shelf life after donation due to detrimental storage effects on their morphological and biochemical properties. Inspired by nature, a biomimetics approach was developed to preserve RBCs for long-term storage using compounds found in animals with a natural propensity to survive in a frozen or desiccated state for decades. Trehalose was employed as a cryoprotective agent and added to the extracellular freezing solution of porcine RBCs. Slow cooling (-1 °C min^-1) resulted in almost complete hemolysis (1 ± 1 % RBC recovery), and rapid cooling rates had to be used to achieve satisfactory cryopreservation outcomes. After rapid cooling, the highest percentage of RBC recovery was obtained by plunging in liquid nitrogen and thawing at 55 °C, using a cryopreservation solution containing 300 mM trehalose. Under these conditions, 88 ± 8 % of processed RBCs were recovered and retained hemoglobin (14 ± 2 % hemolysis). Hemoglobin's oxygen-binding properties of cryopreserved RBCs were not significantly different to unfrozen controls and was allosterically regulated by 2,3-bisphosphoglycerate. These data indicate the feasibility of using trehalose instead of glycerol as a cryoprotective compound for RBCs. In contrast to glycerol, trehalose-preserved RBCs can potentially be transfused without time-consuming washing steps, which significantly facilitates the usage of cryopreserved transfusible units in trauma situations when time is of the essence.

01 Feb 2024·International journal of cosmetic science

Effects of 1,3‐propanediol associated, or not, with butylene glycol and/or glycerol on skin hydration and skin barrier function

Article

Author: Monteiro E Silva, Silas Arandas ; Leonardi, Gislaine Ricci ; Pinto, Juliana Rodrigues

Abstract:

Objective:

This study aimed to assess the effect of 1,3‐propanediol at different concentrations (5%, 10%, or 15%), either applied alone or in combination with butylene glycol (BG) (5%) and/or glycerol (5%), on skin hydration and skin barrier function. The measurements were conducted using capacitance to determine skin hydration and trans epidermal water loss (TEWL) rates to evaluate skin barrier function.

Methods:

A total of 30 healthy female subjects participated in the study. Capacitance and TEWL measurements were conducted at multiple time points, including before application and at 15 min, 2 and 8 h after the humectants were applied to the forearms of the subjects. All the subjects provided written informed consent.

Results:

The 1,3‐propanediol in all concentrations and in all combinations (with BG and/or glycerol) increased skin hydration and improved skin barrier function 15 min, 2 and 8 h after application. Glycerol increased the hydration performance of 1,3‐propanediol. The application of 1,3‐propanediol at a concentration of 15%, either alone or in combination with other humectants, reduced the TEWL to a greater extent than lower concentrations of 1,3‐propanediol. Furthermore, the addition of glycerol to 1,3‐propanediol 15% improved the skin barrier and reduced TEWL when compared with 1,3‐propanediol alone and with the combination of 1,3‐propanediol + BG.

Conclusion:

The humectants significantly improved skin hydration and reduced TEWL throughout the 8‐h time course. The increase in 1,3‐propanediol concentration, as well as its combination with glycerol, provided a greater benefit to the skin, improving both hydration and the skin barrier function.

18 Jan 2024·The journal of physical chemistry. B

Protein Cryoprotectant Ability of the Aqueous Zwitterionic Solution

Article

Author: Kuroda, Kosuke ; Hirata, Tetsuya ; Yamada, Shuto ; Nakayama, Masaharu ; Uto, Takuya ; Takekiyo, Takahiro ; Ishizaki, Takeru ; Yoshimura, Yukihiro

Protein cryopreservation is important for the long-term storage of unstable proteins. Recently, we found that N-acetylglucosaminyltransferase-V (GnT-V) can be cryopreserved in a deep freezer without temperature control using a dilute binary aqueous solution of 3-(1-(2-(2-methoxyethoxy)ethyl)imidazol-3-io)butane-1-carboxylate (OE₂imC₃C) [10 wt %, mole fraction of solute (x) = 7.75 × 10^-3], an artificial zwitterion. However, it is unclear which solvent properties are required in these media to preserve unstable proteins, such as GnT-V. In this study, we investigated the melting phenomena and solution structure of dilute binary aqueous OE₂imC₃C solutions [x = 0-2.96 × 10^-2 (0-30 wt %)] using differential scanning calorimetry (DSC) and Raman and Fourier transform infrared (FTIR) spectroscopies combined with molecular dynamics (MD) simulation to compare the cryoprotectant ability of OE₂imC₃C with two general cryoprotectants (CPAs), glycerol and dimethyl sulfoxide. DSC results indicated that aqueous OE₂imC₃C solutions can be melted at lower temperatures with less energy than the control CPA solution, with increasing x, primarily due to OE₂imC₃C having a higher content of unfrozen water molecules. Moreover, Raman and FTIR results showed that the high content of unfrozen water molecules in aqueous OE₂imC₃C solutions was due to the hydration around the ionic parts (the COO^- group and imidazolium ring) and the OCH₂CH₂O segment. In addition, the MD simulation results showed that there were fewer structured water molecules around the OCH₂CH₂O segment than the hydration water molecules around the ionic parts. These solvent properties suggest that dilute aqueous OE₂imC₃C solutions are effective in preventing freezing, even in a deep freezer. Therefore, this medium has the potential to act as a novel cryoprotectant for proteins in biotechnology and biomedical fields.

News (Medical) associated with Glycerin

10 Jun 2024

·www.biospace.com

Bausch + Lomb INFUSE® for Astigmatism Silicone Hydrogel Daily Disposable Contact Lenses Introduced in the United States

VAUGHAN, Ontario--(BUSINESS WIRE)-- Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. introduction of Bausch + Lomb INFUSE for Astigmatism daily disposable contact lenses. Engineered with a next-generation lens material infused with ProBalance Technology™ and the company’s proprietary OpticAlign® design, INFUSE for Astigmatism provides astigmatic patients clear, stable vision, all-day comfort and minimizes contact lens dryness. The company expects to start shipping INFUSE for Astigmatism fitting sets to eye care professionals in July 2024. “More than half of toric lens wearers with astigmatism experience contact lens dryness and many also report blurred vision. These symptoms are only exacerbated with modern-day lifestyles, which include prolonged digital device use,”1 said Yang Yang, president, Global Vision Care, Bausch + Lomb. “Our INFUSE for Astigmatism lenses, which were developed in-house by our R&D team, are designed to directly address these challenges, including the causes of toric lens rotation. They provide excellent clarity, optimal stability and can be worn comfortably all day.” Consistent with the entire INFUSE family of lenses, INFUSE for Astigmatism features a blend of osmoprotectants, electrolytes and moisturizers, essential comfort and eye health ingredients that are released throughout the 16-hour wearing experience.1 The lens material (kalifilcon A) combines the highest overall moisture (55%) and high breathability (107 Dk/t) with a low modulus for excellent comfort.2,3 INFUSE for Astigmatism is uniquely designed to provide consistently clear vision across the entire power range and help reduce spherical aberration and halos and glare, even in low-light conditions. Engineered with a thin-edge design to minimize lid interaction and a stabilization feature in the lower hemisphere, the cutting-edge OpticAlign design stabilizes with the eye’s natural blink. According to a recent study, 95% of INFUSE for Astigmatism lenses settled within 10 degrees within 30 seconds. In addition, 97% of INFUSE for Astigmatism lenses had less than three degrees of rotation with blink and a mean comfort score of nearly 90%. INFUSE for Astigmatism offers the most in-office parameters and is the only daily disposable toric with -2.25 and -2.75 cylinders available in a fit set.4 "As patient lifestyles become increasingly more dynamic, it's essential their lenses provide a high level of moisture retention and stability, particularly for those with astigmatism. INFUSE for Astigmatism will deliver on these needs and provide comprehensive in-office parameters that make it possible to fit patients during their scheduled appointment,” said Mark Schaeffer, OD, FAAO, and clinical excellence captain, MyEyeDr, Birmingham, Ala. “With this addition to the INFUSE family of lenses – based on the latest ocular surface research – practitioners can be confident that they have an INFUSE lens to meet the majority of their patients’ vision and eye health needs.” Eye care practitioners and contact lens wearers can use Bausch + Lomb’s ONE by ONE recycling program to properly recycle their used contact lens materials, including INFUSE for Astigmatism contact lenses, blister packs and top foils. For more information on the ONE by ONE Recycling program visit . About Astigmatism Astigmatism is a common condition that affects approximately one in three people and occurs when the cornea or lens has a different shape than normal, causing blurry or distorted vision.5,6 It can affect vision of both near and far objects, as well as cause difficulty seeing at night, and coexist with myopia or hyperopia. Astigmatism can be confirmed during a comprehensive eye exam and treated with the use of contact lenses, prescription eyeglasses and/or laser or other surgical procedures.6 About the ONE by ONE Recycling Program The Bausch + Lomb ONE by ONE Recycling program is the first and only contact lens recycling program in the United States. This program collects used contact lenses, top foils and opened plastic blister packs from any brand and is available to contact lens wearers and eye care professionals. To participate, contact lens wearers can bring their used contact lenses and packaging to an official recycling eye care practice, which collects the used materials in a custom recycling bin provided by Bausch + Lomb. Once the bin is filled, the eye care practice ships the materials using a Bausch + Lomb pre-paid shipping label to TerraCycle® where lenses are cleaned and melted into hard plastic pellets that can be used to make new recycled products. To learn more about the Bausch + Lomb ONE by ONE Recycling program, visit . About Bausch + Lomb Bausch + Lomb is dedicated to protecting and enhancing the gift of sight for millions of people around the world – from birth through every phase of life. Its comprehensive portfolio of approximately 400 products includes contact lenses, lens care products, eye care products, ophthalmic pharmaceuticals, over-the-counter products and ophthalmic surgical devices and instruments. Founded in 1853, Bausch + Lomb has a significant global research and development, manufacturing and commercial footprint with approximately 13,000 employees and a presence in nearly 100 countries. Bausch + Lomb is headquartered in Vaughan, Ontario with corporate offices in Bridgewater, New Jersey. For more information, visit and connect with us on X, LinkedIn, Facebook and Instagram. Forward-looking Statements This news release may contain forward-looking statements, which may generally be identified by the use of the words “anticipates,” “hopes,” “expects,” “intends,” “plans,” “should,” “could,” “would,” “will,” “may,” “believes,” “estimates,” “potential,” “target,” or “continue” and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties discussed in Bausch + Lomb’s filings with the U.S. Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Bausch + Lomb undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this news release or to reflect actual outcomes, unless required by law. References Analysis of worn lenses demonstrated poloxamer 181, erythritol, potassium, and glycerin were retained for 16 hours. Oxygen transmissibility at -3.00 diameter. Unlike INFUSE® for Astigmatism, ACUVUE OASYS 1-Day for ASTIGMATISM, MyDay toric, and 1-DAY ACUVUE MOIST for ASTIGMATISM, which are non-surface-treated daily disposables, PRECISION1 for Astigmatism and DAILIES TOTAL1 for Astigmatism are daily disposables with an integrated surface coating. Compared to ACUVUE OASYS 1-Day for ASTIGMATISM, DAILIES TOTAL1 for Astigmatism, and MyDay toric. National Eye Institute: Astigmatism: At a Glance. Accessed May 13, 2024. . Cleveland Clinic: Astigmatism. Accessed May 13, 2024. . © 2024 Bausch + Lomb. IFA.0080.USA.24 View source version on businesswire.com: Contacts Source: Bausch + Lomb Corporation View this news release online at:

29 Apr 2024

·www.biospace.com

Bausch + Lomb Announces Presentation of New Data at the Association for Research in Vision and Ophthalmology Annual Meeting

21 Poster Presentations include Evaluations of Consumer, Pharmaceutical, Surgical and Vision Care Products and Pipeline Programs, Including a Novel Dry Eye Nutritional Supplement VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the presentation of 21 scientific poster presentations during the Association for Research in Vision and Ophthalmology Annual Meeting, which will take place in Seattle May 5-9, 2024. The posters highlight the results of studies evaluating consumer, pharmaceutical, surgical and vision care products from the company’s broad eye care portfolio, as well as pipeline innovations. These include a novel daily nutritional supplement formulated to address dry eye symptoms, which is the focus of two posters as well as a paper published recently in Frontiers in Ophthalmology. “We’re focused on supporting research that advances scientific knowledge of our products and fosters the development of new innovations to serve the holistic needs of eye care professionals and consumers,” said Yehia Hashad, MD, executive vice president, Research & Development and chief medical officer, Bausch + Lomb. “The breadth of data being presented at this meeting, as well as the recent publication evaluating our novel nutritional supplement for dry eyes, Blink™ NutriTears®, underscore this ongoing commitment.” Following is a complete list of titles and lead authors for each of these posters: “Analysis of Glare and its Impact on Retinal Image Quality in Intraocular lenses.” Hosten et al. “A Natural Language Processing Approach to Identify Patients with Uveitic Macular Edema in the IRIS® Registry.” Jin et al. “Clinical Evaluation of a Multi-Ingredient Oral Supplement on Dry Eye Symptoms and Tear Volume.” Barbour et al. “Clinical Evaluation of a Novel Lipid-Containing Eye Drop.” Yassine et al. “Comparison of Clinical Studies from the US and India of a Multi-Ingredient Oral Supplement.” Ryan et al. “Comparison of a Novel Lipid Nano-Emulsion Eye Drop with an Existing Lubricating Eye Drop.” Morrow et al. “Development of an In Vitro Assay to Evaluate the Antioxidant Effects of Erythritol and Glycerin in Human Corneal Epithelial Cells.” VanDerMeid et al. “Effects of Perfluorohexyloctane on the Ocular Pharmacokinetics of Latanoprost and Prednisolone Acetate After Topical Administration to Rabbits.” Cavet et al. “Effects of Perfluorohexyloctane on Corneal Healing in an Ex Vivo Study of Rabbit Corneas.” Alexander et al. “Efficacy of Perfluorohexyloctane Ophthalmic Solution in Patients with Dry Eye Disease Stratified by Baseline Severity.” Sheppard et al. “Enhancing Silicone Oil Removal Efficiency: A Comparative Study of Ultrasonic Vitrectomy Handpieces and Conventional Methods.” Higgins et al. “Evaluating a Novel Contact Solution Among Hydrogen Peroxide Lens Care Users.” Shahidi et al. “Evaluation of the Efficacy of a Novel Preservative-Free Formulation of Brimonidine Tartrate Ophthalmic Solution.” DiVito et al. “Evaluation of Intermediate-Range of Focus with New Monofocal Plus IOLs.” Lau et al. “Evaluation of the Safety of a Novel Preservative-Free Formulation of Brimonidine Tartrate Ophthalmic Solution.” Vollmer et al. “Impact of Pupil Size on Vision Performance of a New Multifocal Daily Disposable Contact Lens.” Reindel et al. “In-Home Use Test of a Novel Contact Lens Solution in Contact Lens Wearers on the Verge of Dropout.” Rah et al. “Intraocular Pressure Optimized Performance Settings with Posterior Adaptive Fluidics (PAF), and 25 Gauge 25,000 cpm Dual-Action Vitrectomy Cutters.” Papour et al. “Phaco Longitudinal Mode Heat Generation, a Two-System Efficiency Comparison Study.” Dickerhoff et al. “Preclinical Toxicity Pro Perfluorohexyloctane Ophthalmic Solution.” Vittitow et al. “Predictive Modeling of Clinical Performance of Novel Trifocal IOL.” Venkateswaran et al. About Bausch + Lomb Bausch + Lomb is dedicated to protecting and enhancing the gift of sight for millions of people around the world – from birth through every phase of life. Its comprehensive portfolio of approximately 400 products includes contact lenses, lens care products, eye care products, ophthalmic pharmaceuticals, over-the-counter products and ophthalmic surgical devices and instruments. Founded in 1853, Bausch + Lomb has a significant global research and development, manufacturing and commercial footprint with approximately 13,000 employees and a presence in nearly 100 countries. Bausch + Lomb is headquartered in Vaughan, Ontario with corporate offices in Bridgewater, New Jersey. For more information, visit and connect with us on X, LinkedIn, Facebook and Instagram. Forward-looking Statements This news release may contain forward-looking statements, which may generally be identified by the use of the words “anticipates,” “hopes,” “expects,” “intends,” “plans,” “should,” “could,” “would,” “will,” “may,” “believes,” “estimates,” “potential,” “target,” or “continue” and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties discussed in Bausch + Lomb’s filings with the U.S. Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Bausch + Lomb undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this news release or to reflect actual outcomes, unless required by law. © 2024 Bausch + Lomb.

06 Feb 2024

·www.prnewswire.com

SUNLESS INC. STEPS INTO BEAUTY, MERGING SCIENCE AND TECHNOLOGY TO CREATE WELLFIT™, AN EFFORTLESS FULL-BODY SKINCARE EXPERIENCE

CLEVELAND, Feb. 6, 2024 /PRNewswire/ -- Sunless, Inc., the company behind VersaSpa® skincare spray systems, today announced the launch of WELLFIT™, a smarter solution to empower healthy full-body confidence in two minutes or less. WELLFIT offers three unique skincare solutions — HYDRATE, LIFT, and RECOVER — as a stand-alone treatment or as an add on to other wellness services to restore, revive and recover the skin's health, boasting a difference users can feel and see. Continue Reading New skincare solution helps restore, revive and recover the skin's health, boasting a difference users can feel and see. Post this Sunless, Inc.'s WELLFIT is a smarter solution to empower healthy full-body confidence in two minutes or less. View PDF Sunless, Inc., makers of VersaSpa® products, steps into beauty, merging science and technology to create an effortless full-body skincare experience. WELLFIT's unique, first-of-their-kind skincare treatments are delivered in a customized spray system offered at participating VersaSpa Pro fitness clubs and tanning salons. WELLFIT has been previewed at several locations throughout the country. More than 85% of users say they "love the way the treatments make the skin feel." WELLFIT users who have experienced the treatments have raved about the difference in their skin, sharing that their usually dry skin felt baby soft and tighter overall after enjoying their refreshing treatment. WELLFIT addresses the need for more approachable skin-focused wellness options, with a recent McKinsey & Co. Future of Wellness survey* citing that 50% of U.S. consumers report wellness as a top priority in their lives, with "better skin appearance" sited as an important pillar in their wellness routine. "The launch of WELLFIT skincare solutions brings to life more than 40 years of skin expertise, combined with smart innovation and technology to produce healthy, glowing skin for all," said Randy Zeno, Sunless, Inc. CEO. This revolutionary concept combines smart technology with unparallel skincare options crafted with clinically tested formulas by Sunless's team of skincare experts. The solutions feature skin-loving ingredients such as hyaluronic acid, vitamins, and essential peptides providing moisture, strength, and a long-lasting glow for healthy-looking skin. This effortless approach to healthy, radiant skin redefines self-care by simplifying your routine and allowing you to focus on feeling your most confident self. WELLFIT is proven to rejuvenate the senses with the infused scents of sea grass and sage. THE WELLFIT EXPERIENCE HYDRATE – Quenches the thirst skin craves. Patented Tri-Hydro Boost Complex™ features a unique formula that allows skin to soak up all the moisture it desires. Active humectants such as glycerin draw moisture deep into the skin, providing immediate suppleness. Impacts multiple layers of skin, restoring the moisture barrier of the skin. The refreshing blend improves skin health maximizing long-term skincare performance. LIFT – Delivers all the firm plumpness skin desires. Features a powerful C-Lift Peptide Complex™ known for its collagen-boosting properties, including vitamins and essential peptides. Helps replenish and restore collagen levels, making skin look healthier, plumper, brighter, and younger. Skin feels instantly smoother, visibly reducing the appearance of surface wrinkles and imperfections for the ultimate firming pick me up. RECOVER – Invigorates your skins health. Crucial electrolytes refuel fatigued skin post activity, providing total body recovery and vital elasticity for skin that bounces back. The activated Nitro+Mineral Complex™ features a cooling blend that instantly energizes the skin's sensations to make it come alive. Vital minerals infuse with the skin to restructure vibrancy and texture for recovery. WELLFIT is available at Sunless, Inc. partner locations in the U.S. and is launching at other locations across the globe throughout the year. WELLFIT will be adding more treatments and skincare products throughout 2024. WELLFIT skincare solutions are here to empower on-the-go, active-lifestyle enthusiasts. All solutions were created to be used as daily treatments, up to three times a week for optimal results. About Sunless/VersaSpa Sunless Inc. is a leader in spray tanning and skincare technology and the power behind the best-known brands — Mystic Tan, Norvell, and VersaSpa — representing more than 18 million spray tans per year, delivered by more than 7,000 salons and professionals worldwide. A holding of Castle Harlan and Branford Castle, Sunless, Inc. is headquartered in Macedonia, Ohio. For more information, images, or quotes from Sunless, Inc., contact Jim Cyphert, APR at 330-501-9886. For more information and available locations, visit: . Instagram: @wellfit.skincare Facebook: wellfit skincare *McKinsey Future of Wellness survey, April 2022, n=2000 SOURCE Sunless, Inc.

100 Deals associated with Glycerin

External Link

KEGG	Wiki	ATC	Drug Bank
D00028	-	A06AX01 A06AG04	DB09462

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Constipation	CN	Tianjin Jinyao Pharmaceutical Co., Ltd.	01 Jan 1981

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02833415 (CTgov)	Phase 4	Obesity, Abdominal \| Diabetes Mellitus	40	[U-13C3] glycerol+Empagliflozin (Empagliflozin)	rvklbchfma(khhffgosws) = uknhxzdhvj usqagrkxar (tgccratuoj, lgkuixjeep - fqasbhbgsj) View more	-	02 May 2019
				Placebo (for Empagliflozin)+[U-13C3] glycerol (Placebo)	rvklbchfma(khhffgosws) = avetcksdmu usqagrkxar (tgccratuoj, rtykxbftul - bkbfaxmwxg) View more
NCT02383758 (CTgov)	Not Applicable	Autism Spectrum Disorder \| Autistic Disorder \| Stool soiling	22	Glycerin Suppository+Bisacodyl suppository+Senna (Treatment Program)	wkyiemzfwq(ysomnqefeu) = eiyuajbqqv qenwplezvr (flhpcvfjcl, irgjexnwzs - fgqrtxkyka) View more	-	11 Jan 2018
				Glycerin Suppository+Bisacodyl suppository+Senna (Waitlist Control)	wkyiemzfwq(ysomnqefeu) = cdkglmfwsp qenwplezvr (flhpcvfjcl, jgfcznxgyp - demfmiffyu) View more
AUA2017	Not Applicable	Visceral Pain	-	JZL 184	updoygoauf(tqayazichg) = vttetnliry nmhyctxkak (fyqwpynudt )	-	01 Apr 2017
				Vehicle	updoygoauf(tqayazichg) = ssepcaccpi nmhyctxkak (fyqwpynudt )
ISRCTN81112701 (Controlled-Trials.com, Pubmed \| J Biol Chem)	Phase 2	Conjunctivochalasis	20	Conheal	rmdgtvltov(nddrfnkvsh) = hmfweyonri kihdlktzoi (mrqblurqjp )	-	01 Jan 2015
TROG 04.01 (Pubmed \| Semin Radiat Oncol)	Not Applicable	-	333	Moisturizing Durable Barrier Cream	ipcgzcxcwf(exhywpktlq) = zaokhgehhi ljwdgrxdqk (yzkjzpnloi )	-	01 May 2013
				10% Glycerine Cream	ipcgzcxcwf(exhywpktlq) = qsgtpdljmt ljwdgrxdqk (yzkjzpnloi )
NCT00681265 (CTgov)	Not Applicable	Kerato conjunctivitis sicca	16	Glycerin (New Formulation of Glycerin 1% Eye Drop)	vzxremyqja(tndgckwpxy) = pwfkimyxpj mwuasgjzkd (noogkvkbhy, pasbdoxyqc - qqcknouahg) View more	-	26 Oct 2012
				Propylene Glycol+PEG 400 (Propylene Glycol and PEG 400 Eye Drop)	vzxremyqja(tndgckwpxy) = ihlkokdpal mwuasgjzkd (noogkvkbhy, manfsmxess - lzcoccgijh) View more
NCT00544713 (CTgov)	Not Applicable	Dry Eye Syndromes	228	Carboxymethylcellulose (Carboxymethylcellulose and Glycerin Based Artificial Tear)	plxthbrnzj(giopifstez) = nfrvimqvjv gidqpegtrq (kqzuebgchk, xtbgjjspoo - afhcoalmuw) View more	-	14 Dec 2011
				Carboxymethylcellulose (Carboxymethylcellulose Based Artificial Tear)	plxthbrnzj(giopifstez) = ulkwxqcxcu gidqpegtrq (kqzuebgchk, ozgoygaqlr - bsmgrqbttu) View more
NCT00333671 (Pubmed \| Invest Ophthalmol Vis Sci)	Not Applicable	Bloodshot eye \| Diabetic macular oedema	18	Peroral Glycerol	dlhlkztuvk(ekfskfryht) = kzkcezjehf astwyjfizs (mvlivsemvc )	-	01 Jun 2010
				Peroral Glycerol	dlhlkztuvk(ekfskfryht) = lrvqfeaudj astwyjfizs (mvlivsemvc )
NCT00681265 (ARVO2009)	Not Applicable	Kerato conjunctivitis sicca	16	New formulation of glycerin 1%	kuqifjbmgk(tsvljphcjn) = thjogfkxqh txahbefwzy (hhcokvgfyt ) View more	-	01 Apr 2009
				Commercially available artificial tear formulation of propylene glycol (0.3%) and polyethylene glycol (0.4%)	etkmpwldkn(yptlbnvinn) = tchrzelapp ldthzsxmgc (jdknskfdjj )
ARVO2003	Not Applicable	-	-	Glycerin	sacvitqlve(txgevscqhn) = jackgqckeu pkuqwvzccy (vporqphqzc )	-	01 May 2003
				Glycerin	sacvitqlve(txgevscqhn) = cmtiossipf pkuqwvzccy (vporqphqzc )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis